 Somatostatin receptors SSTs are expressed by a wide variety of different tumour cell types, including malignant lymphomas. 8, 9, 10, 11 Somatostatin receptor imaging by octreotide scintigraphy has showed a sensitivity of 95-100 in Hodgkins lymphoma and 80 in non-Hodgkins lymphoma. However, somatostatin receptor scintigraphy does not appear to have a significant role in diagnostic process because of the relatively low uptake of the used somatostatin analogue octreotide and limited sensitivity of the single photon emission computed tomography SPECT acquisition to detect and localise small involved nodes. 11, 25 Hence, somatostatin receptor imaging has been further developed with the advent of hybrid SPECT and positron emission tomography PET and computed tomography CT scanners. Several other radioligands have been studied to improve the binding affinity 15. This has also offered a new target for tumor cell-specific therapy using different somatostatin analogs labelled with therapeutic radionuclides such as 90Y-DOTATOC, a somatostatin receptor subtype 2 SST2 -specific ligand. Clinical studies of peptide receptor radionuclide therapy PRRT have extensively focused on neuroendocrine tumors as a palliative treatment modality 12, 13, 14. Another new candidate for SST based imaging and treatment is 68Ga-DOTANOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 SST2, SST3, SST5 16. Neuroendocrine tumors are known to express SST2 and they show high uptake of radiolabeled somatostatin analogs on PET. However, lymphomas may mimick NETs on DOTANOC PETCT as was shown in a recent case report 17. Therefore, further studies on SST2 status and DOTANOC uptake are in order to establish the role of peptide based imaging in diagnosis and possible PRRT in lymphomas. 